Quarterly ResultApr 29, 2026, 07:03 AM
IONS Q1 Revenue +87% to $246M; TRYNGOLZA Sales Guidance >$3B
AI Summary
Ionis Pharmaceuticals reported strong Q1 2026 financial results with total revenue increasing 87% to $246 million, driven by commercial success and $95 million in R&D milestone payments. The company increased its annual TRYNGOLZA peak net sales guidance for severe hypertriglyceridemia (sHTG) to over $3 billion. Key pipeline advancements include Priority Review acceptance for olezarsen in sHTG and zilganersen for Alexander disease, alongside positive Phase 3 data for bepirovirsen.
Key Highlights
- Increased annual TRYNGOLZA peak net sales guidance to >$3B for sHTG.
- Q1 2026 total revenue increased 87% to $246 million YoY.
- Q1 2026 loss from operations improved to $(118) million.
- TRYNGOLZA net product sales were $27 million in Q1 2026.
- DAWNZERA net product sales were $16 million in Q1 2026.
- Olezarsen sNDA for sHTG accepted for Priority Review (PDUFA June 30, 2026).
- Zilganersen NDA for Alexander disease accepted for Priority Review (PDUFA September 22, 2026).